Fulvestrant: A Further Treatment Option for Patients with Metastatic Uterine Cancer?

Publisher： Karger

E-ISSN： 2296-5262|29|12|577-580

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.12, 2006-12, pp. : 577-580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient

By  

Oncology Research and Treatment, Vol. 33, Iss. 1-2, 2010-01 ,pp. : 57-59

Karger

Access to resources Recommend Favorite

Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option

By Cornes Paul   Coiffier Bertrand   Zambrowski Jean-Jacques  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 357-368

Informa Healthcare

Access to resources Recommend Favorite

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 91, Iss. 5, 2016-08 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 476-478

Karger

Access to resources Recommend Favorite

Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 304-308

Karger

Access to resources Recommend Favorite